Iman Imanirad is an Oncology physician affiliated with Moffitt Cancer Center. OpenAlex indexes 78 publications with 642 citations (h-index 14).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
12902 Usf Magnolia Dr
Tampa, FL 33612
Telephone
813-745-1277Provider last certified this registry record 14 May 2026.
Industry payments
13 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Incyte CorporationProgram year202510 payments
- Intera Oncology, IncProgram year20252 payments
- Roche Products LimitedProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
44.4%Opioid Agonist21.3%Oxycodone Hcl58%Tramadol Hcl42%Part D≥17 patientsPhenothiazine18.4%Prochlorperazine Maleate100%Part D≥34 patients+ 1 more class in this area
Metabolism & gastrointestinal
27.4%Serotonin-3 Receptor Antagonist14.1%Ondansetron Hcl100%Part D≥29 patientsAntidiarrheal13.4%Diphenoxylate-Atropine100%Part D≥15 patientsBlood & clotting
9.4%Factor Xa inhibitor9.4%Eliquis100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Comparison of AI-generated radiology impressions: a multi-stakeholder evaluation
npj Digital Medicine
2026 - <i>DPYD</i> testing in GI cancers: A real-world analysis of costs and quality of care.
Journal of Clinical Oncology
2026 - A Guide for Implementing <i>DPYD</i> Genotyping for Systemic Fluoropyrimidines into Clinical Practice
Clinical Pharmacology & Therapeutics
2025 - The Transcriptomic Landscapes of Appendiceal Primary and Metastatic Tumors are Distinct
Annals of Surgical Oncology
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Ignacio Wistuba, MD
Moffitt Cancer Center
Christine Chung, MD
Moffitt Cancer Center
Peter Forsyth, MD
Moffitt Cancer Center
Eric Haura, MD
Moffitt Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”